# GE HealthCare Technologies Inc.: financial statements, quarterly

GEHC · Nasdaq · CIK 1932393 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gehc.md) · [Financials](/companies/gehc/financials.md) · [Filings](/companies/gehc/filings.md) · [Insiders](/companies/gehc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gehc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [4,817](/filings/0001932393-24-000044.md) | [4,822](/filings/0001932393-24-000050.md) | [5,206 d](/filings/0001932393-26-000007.md) | [4,650](/filings/0001932393-25-000014.md) | [4,839](/filings/0001932393-25-000049.md) | [4,863](/filings/0001932393-25-000053.md) | [5,319 d](/filings/0001932393-26-000007.md) | [4,777](/filings/0001932393-26-000031.md) | [5,007](/filings/0001932393-25-000049.md) | [5,143](/filings/0001932393-25-000053.md) | [5,698 d](/filings/0001932393-26-000007.md) | [5,131](/filings/0001932393-26-000031.md) |
| Gross profit | $m | [1,940](/filings/0001932393-24-000044.md) | [1,935](/filings/0001932393-24-000050.md) | [2,156 d](/filings/0001932393-26-000007.md) | [1,902](/filings/0001932393-25-000014.md) | [2,002](/filings/0001932393-25-000049.md) | [2,026](/filings/0001932393-25-000053.md) | [2,275 d](/filings/0001932393-26-000007.md) | [2,012](/filings/0001932393-26-000031.md) | [1,985](/filings/0001932393-25-000049.md) | [1,990](/filings/0001932393-25-000053.md) | [2,261 d](/filings/0001932393-26-000007.md) | [1,977](/filings/0001932393-26-000031.md) |
| Research and development | $m | [298](/filings/0001932393-24-000044.md) | [322](/filings/0001932393-24-000050.md) | [315 d](/filings/0001932393-26-000007.md) | [324](/filings/0001932393-25-000014.md) | [327](/filings/0001932393-25-000049.md) | [316](/filings/0001932393-25-000053.md) | [344 d](/filings/0001932393-26-000007.md) | [344](/filings/0001932393-26-000031.md) | [302](/filings/0001932393-25-000049.md) | [292](/filings/0001932393-25-000053.md) | [323 d](/filings/0001932393-26-000007.md) | [345](/filings/0001932393-26-000031.md) |
| Selling, general and administrative | $m | [1,072](/filings/0001932393-24-000044.md) | [996](/filings/0001932393-24-000050.md) | [1,152 d](/filings/0001932393-26-000007.md) | [1,038](/filings/0001932393-25-000014.md) | [1,067](/filings/0001932393-25-000049.md) | [1,034](/filings/0001932393-25-000053.md) | [1,130 d](/filings/0001932393-26-000007.md) | [1,040](/filings/0001932393-26-000031.md) | [1,029](/filings/0001932393-25-000049.md) | [1,045](/filings/0001932393-25-000053.md) | [1,111 d](/filings/0001932393-26-000007.md) | [1,117](/filings/0001932393-26-000031.md) |
| Operating income | $m | [570](/filings/0001932393-24-000044.md) | [617](/filings/0001932393-24-000050.md) | [689 d](/filings/0001932393-26-000007.md) | [540](/filings/0001932393-25-000014.md) | [608](/filings/0001932393-25-000049.md) | [676](/filings/0001932393-25-000053.md) | [801 d](/filings/0001932393-26-000007.md) | [629](/filings/0001932393-26-000031.md) | [654](/filings/0001932393-25-000049.md) | [653](/filings/0001932393-25-000053.md) | [827 d](/filings/0001932393-26-000007.md) | [515](/filings/0001932393-26-000031.md) |
| Income tax | $m | [137](/filings/0001932393-24-000044.md) | [250](/filings/0001932393-24-000050.md) | [193 d](/filings/0001932393-26-000007.md) | [124](/filings/0001932393-25-000014.md) | [143](/filings/0001932393-25-000049.md) | [168](/filings/0001932393-25-000053.md) | [96.0 d](/filings/0001932393-26-000007.md) | [104](/filings/0001932393-26-000031.md) | [113](/filings/0001932393-25-000049.md) | [179](/filings/0001932393-25-000053.md) | [219 d](/filings/0001932393-26-000007.md) | [94.0](/filings/0001932393-26-000031.md) |
| Net income | $m | [418](/filings/0001932393-24-000044.md) | [375](/filings/0001932393-24-000050.md) | [403 d](/filings/0001932393-26-000007.md) | [374](/filings/0001932393-25-000014.md) | [428](/filings/0001932393-25-000049.md) | [470](/filings/0001932393-25-000053.md) | [721 d](/filings/0001932393-26-000007.md) | [564](/filings/0001932393-26-000031.md) | [486](/filings/0001932393-25-000049.md) | [446](/filings/0001932393-25-000053.md) | [589 d](/filings/0001932393-26-000007.md) | [389](/filings/0001932393-26-000031.md) |
| Diluted EPS | $ per share | [0.91](/filings/0001932393-24-000044.md) | [0.82](/filings/0001932393-24-000050.md) | not reported | [0.81](/filings/0001932393-25-000014.md) | [0.93](/filings/0001932393-25-000049.md) | [1.02](/filings/0001932393-25-000053.md) | not reported | [1.23](/filings/0001932393-26-000031.md) | [1.06](/filings/0001932393-25-000049.md) | [0.98](/filings/0001932393-25-000053.md) | not reported | [0.85](/filings/0001932393-26-000031.md) |
| Basic EPS | $ per share | [0.92](/filings/0001932393-24-000044.md) | [0.82](/filings/0001932393-24-000050.md) | not reported | [0.82](/filings/0001932393-25-000014.md) | [0.94](/filings/0001932393-25-000049.md) | [1.03](/filings/0001932393-25-000053.md) | not reported | [1.23](/filings/0001932393-26-000031.md) | [1.06](/filings/0001932393-25-000049.md) | [0.98](/filings/0001932393-25-000053.md) | not reported | [0.85](/filings/0001932393-26-000031.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [1.9](/filings/0001932393-23-000112.md) | [2.4](/filings/0001932393-23-000125.md) | [2.5](/filings/0001932393-25-000005.md) | [2.6](/filings/0001932393-24-000034.md) | [2.0](/filings/0001932393-24-000044.md) | [3.6](/filings/0001932393-24-000050.md) | [2.9](/filings/0001932393-26-000007.md) | [2.5](/filings/0001932393-25-000014.md) | [3.7](/filings/0001932393-25-000049.md) | [4.0](/filings/0001932393-25-000053.md) | [4.5](/filings/0001932393-26-000031.md) | [2.3](/filings/0001932393-26-000031.md) |
| Current assets | $bn | [9.2](/filings/0001932393-23-000112.md) | [9.5](/filings/0001932393-23-000125.md) | [9.4](/filings/0001932393-25-000005.md) | [9.4](/filings/0001932393-24-000034.md) | [8.8](/filings/0001932393-24-000044.md) | [10.6](/filings/0001932393-24-000050.md) | [9.9](/filings/0001932393-26-000007.md) | [9.7](/filings/0001932393-25-000014.md) | [11.3](/filings/0001932393-25-000049.md) | [11.9](/filings/0001932393-25-000053.md) | [12.5](/filings/0001932393-26-000031.md) | [10.4](/filings/0001932393-26-000031.md) |
| Total assets | $bn | [32.3](/filings/0001932393-23-000112.md) | [32.4](/filings/0001932393-23-000125.md) | [32.5](/filings/0001932393-25-000005.md) | [32.2](/filings/0001932393-24-000034.md) | [31.9](/filings/0001932393-24-000044.md) | [33.9](/filings/0001932393-24-000050.md) | [33.1](/filings/0001932393-26-000007.md) | [33.6](/filings/0001932393-25-000014.md) | [35.5](/filings/0001932393-25-000049.md) | [36.1](/filings/0001932393-25-000053.md) | [36.9](/filings/0001932393-26-000031.md) | [37.1](/filings/0001932393-26-000031.md) |
| Current liabilities | $bn | [7.6](/filings/0001932393-23-000112.md) | [7.6](/filings/0001932393-23-000125.md) | [9.0](/filings/0001932393-25-000005.md) | [8.9](/filings/0001932393-24-000034.md) | [8.3](/filings/0001932393-24-000044.md) | [8.7](/filings/0001932393-24-000050.md) | [9.6](/filings/0001932393-26-000007.md) | [10.0](/filings/0001932393-25-000014.md) | [9.7](/filings/0001932393-25-000049.md) | [10.1](/filings/0001932393-25-000053.md) | [9.1](/filings/0001932393-26-000031.md) | [8.5](/filings/0001932393-26-000031.md) |
| Total liabilities | $bn | [25.0](/filings/0001932393-23-000112.md) | [25.1](/filings/0001932393-23-000125.md) | [25.1](/filings/0001932393-25-000005.md) | [24.6](/filings/0001932393-24-000034.md) | [23.9](/filings/0001932393-24-000044.md) | [25.3](/filings/0001932393-24-000050.md) | [24.4](/filings/0001932393-26-000007.md) | [24.2](/filings/0001932393-25-000014.md) | [25.5](/filings/0001932393-25-000049.md) | [25.9](/filings/0001932393-25-000053.md) | [26.3](/filings/0001932393-26-000031.md) | [26.2](/filings/0001932393-26-000031.md) |
| Long-term debt | $bn | [10.2](/filings/0001932393-23-000112.md) | [10.3](/filings/0001932393-23-000125.md) | [8.4](/filings/0001932393-25-000005.md) | [8.2](/filings/0001932393-24-000034.md) | [8.2](/filings/0001932393-24-000044.md) | [9.3](/filings/0001932393-24-000050.md) | [7.4](/filings/0001932393-26-000007.md) | [6.8](/filings/0001932393-25-000014.md) | [8.3](/filings/0001932393-25-000049.md) | [8.3](/filings/0001932393-25-000053.md) | [9.5](/filings/0001932393-26-000031.md) | [10.1](/filings/0001932393-26-000031.md) |
| Current portion of debt | $bn | [0.0](/filings/0001932393-23-000112.md) | [0.0](/filings/0001932393-23-000125.md) | [1.0](/filings/0001932393-25-000005.md) | [1.0](/filings/0001932393-24-000034.md) | [1.0](/filings/0001932393-24-000044.md) | [1.0](/filings/0001932393-24-000050.md) | [1.5](/filings/0001932393-26-000007.md) | [2.0](/filings/0001932393-25-000014.md) | [2.0](/filings/0001932393-25-000049.md) | [2.0](/filings/0001932393-25-000053.md) | [0.5](/filings/0001932393-26-000031.md) | [0.0](/filings/0001932393-26-000031.md) |
| Short-term borrowings | $bn | [0.0](/filings/0001932393-23-000112.md) | [0.0](/filings/0001932393-23-000125.md) | [1.0](/filings/0001932393-25-000005.md) | [1.0](/filings/0001932393-24-000034.md) | [1.0](/filings/0001932393-24-000044.md) | [1.0](/filings/0001932393-24-000050.md) | [1.5](/filings/0001932393-26-000007.md) | [2.0](/filings/0001932393-25-000014.md) | [2.0](/filings/0001932393-25-000049.md) | [2.0](/filings/0001932393-25-000053.md) | [0.5](/filings/0001932393-26-000031.md) | [0.0](/filings/0001932393-26-000031.md) |
| Shareholders' equity | $bn | [7.1](/filings/0001932393-23-000112.md) | [7.1](/filings/0001932393-23-000125.md) | [7.1](/filings/0001932393-25-000005.md) | [7.4](/filings/0001932393-24-000034.md) | [7.8](/filings/0001932393-24-000044.md) | [8.3](/filings/0001932393-24-000050.md) | [8.4](/filings/0001932393-26-000007.md) | [9.2](/filings/0001932393-25-000014.md) | [9.7](/filings/0001932393-25-000049.md) | [10.0](/filings/0001932393-25-000053.md) | [10.4](/filings/0001932393-26-000031.md) | [10.7](/filings/0001932393-26-000031.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(67.0) d](/filings/0001932393-24-000044.md) | [650 d](/filings/0001932393-23-000125.md) | [1,050 d](/filings/0001932393-26-000007.md) | [419](/filings/0001932393-25-000014.md) | [(119) d](/filings/0001932393-25-000049.md) | [742 d](/filings/0001932393-25-000053.md) | [913 d](/filings/0001932393-26-000007.md) | [250](/filings/0001932393-26-000031.md) | [94.0 d](/filings/0001932393-25-000049.md) | [593 d](/filings/0001932393-25-000053.md) | [1,050 d](/filings/0001932393-26-000007.md) | [290](/filings/0001932393-26-000031.md) |
| Capital expenditure | $m | [70.0 d](/filings/0001932393-23-000112.md) | [80.0 d](/filings/0001932393-24-000050.md) | [94.0 d](/filings/0001932393-26-000007.md) | [145](/filings/0001932393-25-000014.md) | [64.0 d](/filings/0001932393-25-000049.md) | [90.0 d](/filings/0001932393-25-000053.md) | [102 d](/filings/0001932393-26-000007.md) | [152](/filings/0001932393-26-000031.md) | [86.0 d](/filings/0001932393-25-000049.md) | [110 d](/filings/0001932393-25-000053.md) | [134 d](/filings/0001932393-26-000007.md) | [178](/filings/0001932393-26-000031.md) |
| Dividends paid | $m | [14.0 d](/filings/0001932393-24-000044.md) | [14.0 d](/filings/0001932393-24-000050.md) | [13.0 d](/filings/0001932393-26-000007.md) | [14.0](/filings/0001932393-25-000014.md) | [14.0 d](/filings/0001932393-25-000049.md) | [13.0 d](/filings/0001932393-25-000053.md) | [14.0 d](/filings/0001932393-26-000007.md) | [16.0](/filings/0001932393-26-000031.md) | [16.0 d](/filings/0001932393-25-000049.md) | [16.0 d](/filings/0001932393-25-000053.md) | [16.0 d](/filings/0001932393-26-000007.md) | [16.0](/filings/0001932393-26-000031.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001932393-25-000053.md) | [0.0 d](/filings/0001932393-26-000007.md) | [0.0](/filings/0001932393-26-000031.md) | [100 d](/filings/0001932393-25-000049.md) | [100 d](/filings/0001932393-25-000053.md) | [0.0 d](/filings/0001932393-26-000007.md) | [100](/filings/0001932393-26-000031.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities, us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment, us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | period not labelled (2022-06-30) | period not labelled (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [454](/filings/0001932393-23-000112.md) | [454](/filings/0001932393-23-000125.md) | [457](/filings/0001932393-24-000034.md) | [458](/filings/0001932393-24-000044.md) | [458](/filings/0001932393-24-000050.md) | [459](/filings/0001932393-25-000014.md) | [459](/filings/0001932393-25-000049.md) | [459](/filings/0001932393-25-000053.md) | [459](/filings/0001932393-26-000031.md) | [458](/filings/0001932393-25-000049.md) | [457](/filings/0001932393-25-000053.md) | [457](/filings/0001932393-26-000031.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 454,891,786 at 2026-04-22, from the cover of the [10-Q filed 2026-04-29](/filings/0001932393-26-000031.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.